Nabla Bio
Assembly Line
Nabla Bio Secures $26M Series A Financing and Collaborations with AstraZeneca, Bristol Myers Squibb and Takeda for Generative Protein Design
Nabla Bio (aka “Nabla”), pioneers in generative protein design, announced the close of a $26 million Series A financing, led by Radical Ventures with participation from all existing investors, and strategic collaborations with AstraZeneca, Bristol Myers Squibb Company and Takeda, worth more than $550 million in upfront and milestone payments, plus royalties.
Nabla develops integrated AI and wet-lab technologies that enable atomically precise drug design and high-throughput measurement of drug function, with an initial focus on antibodies targeting multipass membrane proteins, including for example, G protein-coupled receptors (GPCRs), ion channels, and transporte